Compare STNG & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STNG | ICUI |
|---|---|---|
| Founded | 2009 | 1984 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | 2010 | 1992 |
| Metric | STNG | ICUI |
|---|---|---|
| Price | $51.26 | $146.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $69.20 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 1.2M | 255.7K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.88 | N/A |
| Revenue | $889,539,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.54 | N/A |
| P/E Ratio | $8.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.63 | $107.00 |
| 52 Week High | $65.52 | $175.51 |
| Indicator | STNG | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 26.55 | 59.51 |
| Support Level | $51.14 | $145.32 |
| Resistance Level | $52.38 | $148.95 |
| Average True Range (ATR) | 1.30 | 4.01 |
| MACD | -0.42 | -0.63 |
| Stochastic Oscillator | 8.92 | 65.40 |
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.